Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Breathlessness mystery: can a finger device predict side effects in myeloma treatment?

NCT ID NCT04827563

Knowledge-focused Sponsor: University of Chicago Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study aimed to find out why some multiple myeloma patients develop shortness of breath when taking the drug carfilzomib. Researchers used an FDA-approved finger device called EndoPAT to check blood vessel health and tracked symptoms through surveys. The study enrolled 50 adults with newly diagnosed or relapsed multiple myeloma who were already receiving carfilzomib. The goal was to gather information to better prevent this side effect in the future.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
carfilzomib
What this could lead to
If successful, this could help doctors predict and prevent shortness of breath in multiple myeloma patients receiving carfilzomib.
What could go wrong
This is a small, terminated pilot study, so results may be limited. It does not test a new treatment, only gathers information.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

50 people

The number who actually took part.

Started

Mar 2021

Finished

Sep 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Participants with multiple myeloma who are being treated with carfilzomib.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥ 18 * Confirmed diagnosis of multiple myeloma * Newly-diagnosed multiple myeloma, or relapsed/refractory multiple myeloma with receipt of 1-3 previous lines of therapy and with a 2-week washout from prior therapy * Receiving carfilzomib as either standard-of-care therapy or as part of a clinical trial Exclusion Criteria: * Previous receipt of anthracycline chemotherapy * Previous receipt of carfilzomib * Four or more previous lines of therapy * Active pregnancy at the time of enrollment

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cardiotoxicity are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Cardiotoxicity Dyspnea plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cardiotoxicity Dyspnea Multiple myeloma Shortness of breath

Contacts and locations

Locations

  • University of Chicago

    Chicago, Illinois, 60637, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.